Skip to main content

Table 1 Performance of the 7-AAb panel and AFP in HCC detection

From: Autoantibody signature in hepatocellular carcinoma using seromics

Phase Detectiona HCC vs. (healthy + cirrhotic) HCC vs. healthy HCC vs. cirrhotic
AUC Specificity Sensitivity AUC Specificity Sensitivity AUC Specificity Sensitivity
Test Phase (II) AFP 0.808 98.7% 28.4% 0.821 100.0% 28.4% 0.789 96.7% 28.4%
ANN 0.894 92.1% 68.6% 0.933 93.3% 77.5% 0.838 90.2% 61.6%
AFP + ANN 0.924 92.1% 78.6% 0.959 96.3% 84.1% 0.873 92.4% 71.6%
Validation Phase (III) AFP 0.822 99.6% 30.7% 0.822 100.0% 30.7% 0.823 98.8% 30.7%
ANN 0.902 90.1% 73.4% 0.928 93.4% 77.5% 0.853 96.3% 62.2%
AFP + ANN 0.932 90.1% 82.0% 0.953 93.4% 83.9% 0.893 95.1% 73.0%
Test phase (II) + validation phase (III) AFP 0.815 99.1% 29.6% 0.821 100.0% 29.6% 0.805 97.7% 29.6%
ANN 0.898 90.0% 71.6% 0.930 92.7% 77.7% 0.845 90.8% 64.1%
AFP + ANN 0.928 93.7% 77.0% 0.956 93.4% 85.1% 0.882 91.3% 73.0%
  1. aThe diagnostic cutoff value of AFP was 400 ng/mL